CD33 and neoplasm: Post-treatment analyses showed that compared to non-treated tumor cells, the tumor cells remaining after CAR33-T cell treatment were CD33-negative/low and exhibited elevated levels of CSC markers such as SOX2 and OCT3/4 (Fig. 5q, r).